# P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

> **NCT06468033** · PHASE3 · RECRUITING · sponsor: **PharmaEssentia** · enrollment: 150 (estimated)

## Conditions studied

- Primary Myelofibrosis
- Myeloproliferative Neoplasm

## Interventions

- **BIOLOGICAL:** Ropeginterferon alfa-2b
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06468033
- **Lead sponsor:** PharmaEssentia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468033, "P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06468033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*